Cancer diagnostics company Lucid Diagnostics Inc (Nasdaq:LUCD) said on Wednesday that it has priced its initial public offering (IPO) of 5,000,000 shares of its common stock.
All of the shares in the IPO are being offered by the company at a price of USD14.00 per share for expected gross proceeds of USD70m, before deducting underwriting discounts, commissions and other offering expenses.
The company has provided the underwriters with a 30-day option to purchase up to an additional 750,000 shares of common stock from Lucid at the initial public offering price less underwriting discounts and commissions.
For the offering, Cantor and Canaccord Genuity are acting as joint book-running managers. BTIG and Needham & Company are acting as co-lead managers. The offering is expected to close on or about 18 October 2021, subject to the satisfaction of customary closing conditions.
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study